Fusidic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Fusidic Acid: Exposure keratitis
One-Sentence Summary
Fusidic acid is an antibacterial agent used mainly against Gram-positive infections, especially Staphylococcus. The TxGNN model predicts it may be effective for exposure keratitis, but there are 0 clinical trials and only 1 publication (a case series on a different organism) behind this prediction, so the evidence is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Exposure keratitis |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Fusidic acid inhibits bacterial protein synthesis by binding elongation factor G. Its activity is mainly against Gram-positive organisms such as Staphylococcus. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description relies on the general understanding of the drug.
Exposure keratitis is mainly a mechanical or desiccation disorder of the cornea, in which the surface dries out because the eyelids do not close properly. Antibacterial activity would only matter if a secondary infection developed. The one retrieved paper is a case series of ocular Tsukamurella infections. It is not a study of fusidic acid in exposure keratitis. The link between the original indications and this prediction is therefore indirect and speculative.
It is worth noting that a licensed ophthalmic product (FUCITHALMIC) is already marketed in Canada. This suggests ocular use for bacterial infection is established, but that is different from evidence for exposure keratitis itself.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31246677 | 2019 | Case series | Cornea | Largest case series of Tsukamurella-associated ophthalmic infections, covering clinical spectrum, risk factors, treatment and outcome. It does not study fusidic acid in exposure keratitis. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02243862 | FUCITHALMIC | Not specified | Not specified |
| 00586668 | FUCIDIN CREAM 2% | Not specified | Not specified |
| 00586676 | FUCIDIN OINTMENT 2% | Not specified | Not specified |
| 02528096 | TARO-FUSIDIC ACID | Not specified | Not specified |
| 02474883 | FUCIBET | Not specified | Not specified |
A sixth authorization, FUCIDIN H (DIN 02238578), is also valid. All 6 of 6 licenses are valid.
Safety Considerations
The knowledge graph lists the following conditions as contraindication-related for this drug. These come from graph relationships, not from package insert text, and should be verified against the label:
- Hepatic and renal: liver failure, liver disease, kidney disease, gallbladder disease
- Ocular: herpes simplex virus keratitis, open-angle glaucoma, glaucoma, ocular hypertension, eye infectious disease, conjunctivitis
- Metabolic: diabetes mellitus, diabetic ketoacidosis, potassium deficiency, hypercalcemia, nephrocalcinosis, phosphorus metabolism disease
- Cardiac: atrial fibrillation, atrioventricular block, Adams-Stokes syndrome, Wolff-Parkinson-White syndrome
- Gastrointestinal: Clostridium difficile colitis, colitis, perinatal necrotizing enterocolitis, dyskinesia of esophagus
- Neuromuscular and respiratory: myasthenia gravis, neuromuscular junction disease, respiratory failure, central nervous system origin vertigo
- Other: pyoureter
Several of these entries (for example the cardiac and metabolic ones) look unusual for fusidic acid, which suggests the graph may mix in class-level or combination-product signals (the Canadian list includes combination-type brands such as FUCIDIN H and FUCIBET). They should be interpreted cautiously.
No drug interaction records were found. Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no clinical trials exist and the single publication is an unrelated-organism case series. Exposure keratitis is mainly a non-infectious surface disorder, so the mechanistic link is weak. The package insert safety information has also not yet been obtained.
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada, plus approved indication text and dosage forms for each DIN
- Detailed mechanism-of-action data
- Evidence on whether fusidic acid has any role in infected or secondary exposure keratitis, including ophthalmic-use clinical data
- Review of the other predictions, in particular otitis externa (score 0.9984, 5 supporting microbiology papers, mostly canine). It has a more plausible mechanism, as typical pathogens such as S. aureus are within fusidic acid’s spectrum. However, there are no clinical studies, and it may reflect an existing use rather than a novel one. It may be a better candidate for a research question than exposure keratitis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.